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ASSESSING CARDIOVASCULAR DISEASE RISK  
IN WOMEN NEWLY DIAGNOSED WITH BREAST CANCER 
This prospective, descriptive study was designed to explore the baseline cardiovascular 
disease (CVD) risk factors of women newly diagnosed with breast cancer prior to receiving 
treatment with anthracyclines and/or trastuzumab. Women diagnosed with breast cancer are at 
risk for developing CVD and may experience increased risk factors related to breast cancer 
diagnoses and treatments. The specific aim was to determine baseline cardiovascular risk 
through the use of the Framingham General Cardiovascular Risk Assessment Score (FGCVRAS) 
calculation and heart/vascular age calculation. Subjects included 30 women (mean age 49.97). 
Mean FGCVRAS was 5.58% (SD 5.68), and mean heart/vascular age was 49.62 years (SD 
18.33) with 9 women having heart/vascular ages that exceeded their actual ages. At a 
cardiovascular risk of approximately 5.3%, vascular age began to exceed actual age. At baseline, 
only 3 of the 30 women had ever had a cardiovascular risk assessment, 14 women had at least 
two CVD risk factors, and 6 women met diagnostic criteria for metabolic syndrome. Multiple 
regression showed that HDL, glucose, waist circumference, and mean systolic blood pressure 
most contributed to CVD risk as calculated by the FGCVRAS. At baseline, women diagnosed 
with breast cancer demonstrate a significant risk burden for CVD that needs to be assessed and 
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The Clinical Problem 
Statement of the Problem 
  Overall survival and quality of life are key treatment outcomes for breast cancer 
survivors.  Breast cancer remains the most common cancer among women in the United States, 
with 2,591,855 having reported diagnoses of breast cancer.1  Risk increases in women ages 40-
49 and continues to increase with age.1  With current therapies, the five-year survival rate for 
breast cancer is 89% overall, and 100% for carcinoma in situ.1  The American Cancer Society 
estimates that there are 2.5 million breast cancer survivors in the United States alone.2 With 
improving breast cancer survival rates, competing causes of death have emerged and contributed 
to increased mortality, including cardiovascular disease.3 CVD risk increases after age 40,4 
correlating closely with the age that breast cancer risk also increases.1  
As the length of survival after breast cancer therapy continues to increase, the potential 
impact of cardiovascular risk (CVR) becomes an important consideration for clinicians, 
especially in combination with the cardiotoxic side effects of breast cancer therapy. 
Cardiotoxicity as both a short- and long-term effect of cancer therapy results in decreased quality 
of survival.5 It has been well documented in women with breast cancer as a result of treatment 
with anthracyclines,6-13 trastuzumab,8-91011, 13-18 and radiation therapy,10, 11, 19-24 with risks 
including cardiac dysfunction, weight gain, and increased waist circumference.7, 14, 17, 18, 25 
Endocrine therapy, resulting in marked decreases in estrogen levels, also raises concern about 
potential cardiovascular risks.26-34 Consequently, not only are women faced with a high lifetime 
risk of developing CVD, but they may also be at an increased risk because of their breast cancer 
diagnoses and treatments.  
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In the United States, CVD is the number one cause of death, accounting for one out of 
every 2.9 deaths.4 Furthermore, one in three adults in the United States has CVD, and the risk of 
having CVD increases after age 40; women who are free of CVD at age 40 still have a greater 
than 50% lifetime risk for developing it, and women who are free of CVD at age 50 continue to 
have a high lifetime risk of 39.2%.4 Non-breast cancer-related health issues, and specifically 
CVD, continue to be a common cause of death among breast cancer survivors, 34-40 
demonstrating the importance of screening for, preventing, and treating CVD in this at-risk 
population, even in asymptomatic patients.4, 41-43 
Despite this evidence, there are significant barriers to reducing cardiovascular morbidity 
and mortality related to cancer treatment. Patients must be screened for cardiac risk factors, and 
pre-existing cardiac disease must be treated in a manner that complements cancer treatment.44 
Standard tests utilized to detect cardiac damage have low sensitivity,39 new targeted therapies 
also have cardiovascular side effects, 39, 40 and there is currently no known way to evaluate 
subclinical disease.39, 44-48 Furthermore, even with guidelines recommending screening and risk 
assessments, healthcare provider compliance has been inconsistent.49, 50 Providers describe 
barriers to addressing CVD risk, including insurance coverage regarding lifestyle interventions, 
lack of time, and the patients themselves.49, 50 Also, despite similar calculated risk for female and 
male patients, providers were more likely to describe their female patients as at lower risk for 
cardiac disease.50 Consequently, women newly diagnosed with breast cancer may begin 
treatment without ever having cardiovascular risk assessed by a primary care provider. 
Furthermore, although there are national guidelines in place for cardiovascular risk assessments 
in the general population, there are no standards for risk assessments before or after breast cancer 
treatment, despite evidence that they are needed.41, 44 
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 In summary, women diagnosed with breast cancer continue to be at risk for developing 
CVD and may experience increased risk factors related to their breast cancer diagnoses and 
treatment with anthracyclines and/or trastuzumab. This study was designed to determine the 
cardiovascular risk of women newly diagnosed with breast cancer prior to receiving treatment 
with anthracyclines and/or trastuzumab. The following research questions guided the study: 
1. What is the Framingham General Cardiovascular Risk Assessment Score of women 
newly diagnosed with breast cancer? 
2. What is the heart/vascular age calculation of women newly diagnosed with breast cancer? 
Review of the Literature 
Cardiovascular risks. 
 Cardiovascular risks factors were first developed by the Framingham Heart Study, which 
sought to determine factors that predict cardiac disease based on mathematical models.51 The 
Framingham Heart Study developed risk scores by which risk of coronary heart disease (CHD) 
events could be predicted mathematically based on major CHD risk factors; these included sex, 
age, blood pressure, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein 
(HDL), smoking, and diabetes. This resulted in the development of the Framingham Risk 
Assessment for Coronary Heart Disease (FRACHD), a multivariate assessment utilized to 
estimate risk of atherosclerotic CVD. Blood pressure and cholesterol categories were ultimately 
added to this assessment score in accordance with Fifth Joint National Committee on 
Hypertension (JNC-V) and the National Cholesterol Education Program Adult Treatment Panel 
II recommendations.52, 53 Original assessments have changed over time, and now include age, 
total cholesterol, HDL, systolic blood pressure, use of anti-hypertensive medications, smoking, 
and diabetes. Other risk factors, including abdominal obesity, left ventricular hypertrophy, 
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insulin resistance, high triglycerides, and family history have been identified, as well.52, 53 As 
medical understanding of the processes underlying atherosclerosis became apparent, it was 
recognized that, while useful in predicting high risk, a low score on the FRACHD was 
insufficient to define low risk, especially in women.43 This resulted in the development of the 
Framingham General Cardiovascular Risk Assessment Score (FGCVRAS), which is a broader 
multivariate risk assessment of general 10-year CVD risk and the risk of individual CVD events, 
as well as a method for describing vascular age.43 It encompasses more than atherosclerotic 
CVD, and includes risk of CHD, cerebral vascular events, peripheral artery disease, and heart 
failure.52, 53 
Metabolic syndrome. 
 Metabolic syndrome refers to a group of metabolic risk factors – known CVD risk 
factors, including obesity, hyperglycemia, dyslipidemia, and hypertension – as well as the 
underlying risk factors that promote the development of metabolic syndrome, including obesity. 
54, 55 Metabolic syndrome has been associated with increased risk of CVD, especially in men 
aged 45 years and older and women aged 55 years and older.56 The FRACHD provides a 
superior prediction of CVD, although a diagnosis of metabolic syndrome may convey additional 
risk factors, and thus complement the FRACHD.56  
Several organizations have statements defining metabolic syndrome with specific 
diagnostic criteria, including the National Cholesterol Education Program Adult Treatment Panel 
III (NCEP ATP III), the World Health Organization (WHO), the European Group for the Study 
of Insulin Resistance (EGIR), and the International Diabetes Federation (IDF). There is no true 
consensus on the components that define metabolic syndrome; while the definitions put forth by 
each of these groups differ slightly, they all include glucose intolerance or insulin resistance, 
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obesity, hypertension, and dyslipidemia.55, 57, 58 They all predict increased risk of CVD 
independent of age, sex, ethnicity, history of CVD or type 2 diabetes mellitus (T2DM), non-HDL 
cholesterol, smoking status, and family history with similar odds ratios but different sensitivities 
and levels of false positive.56  
The common characteristics of metabolic syndrome often create prothrombotic and 
proinflammatory states that serve as increased risks for CVD, as well.54 The largest underlying 
risk factors of metabolic syndrome are abdominal obesity and insulin resistance; other non-
traditional risk factors of metabolic syndrome include markers of inflammation (including 
elevated C-reactive protein levels), thrombophilia, and endothelial dysfunction.54, 57  
 While each of the components of metabolic syndrome is a known cardiovascular risk 
factor, the presence of metabolic syndrome itself is also an important independent indicator of 
cardiovascular risk. Metabolic syndrome allows for the identification of patients at increased risk 
for CVD, and, depending on the diagnostic criteria utilized, is associated with two to four times 
the risk of CVD, a risk that is higher in women than men and is of increasing concern in persons 
with diabetes, pre-existing CVD, or chronic inflammation.55, 57 Wilson et al. reported a baseline 
prevalence of 12.5% in women aged 51 years, with an increase to 30.6% over eight years.59 This 
corresponded with relative risks of 2.25 for CVD (95% CI 1.31-3.88), and 1.54 for total coronary 
heart disease (95% CI 0.68-3.53).59 This study shows that prevalence of metabolic syndrome 
increases with age and corresponds with CVD. It is important to note, however, that even in 
persons with a low short-term (ten years, for example) risk of CVD or T2DM, their lifetime risks 
remain high.54  
 CVD risk factors show an additive effect on cardiovascular risk; metabolic syndrome and 
risk for CVD also exhibit these additive properties.59 Furthermore, the components of metabolic 
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syndrome are interrelated, and ultimately linked to endothelial dysfunction.55 Metabolic 
syndrome provides a framework for these relationships and for the understanding of increased 
risks associated with them. However, in terms of cardiovascular risk, the American Heart 
Association and National Heart, Lung, and Blood Institute continue to recognize metabolic 
syndrome as a secondary target for reduction of cardiovascular events, while maintaining that 
other well-established factors, such as smoking cessation, lowering LDL cholesterol levels, and 
managing blood pressure, should continue to be the primary targets of interventions.54  
 Hypertension. 
 Increases in blood pressure are related to increased risks in cardiovascular events.54, 57 
Increased blood pressure results in damage to vascular walls and endothelial dysfunction; these 
results have been seen even in small increases in blood pressure.57 Overt hypertension should be 
treated to a goal of <140/90 mmHg; in the presence of other chronic conditions, such as diabetes 
or chronic kidney disease, blood pressure goals should be lower at <130/80 mmHg.54 
 Diabetes mellitus. 
Diabetes is a major risk factor for atherosclerosis, increasing the risk of myocardial 
infarction roughly two-fold in men and four-fold in women.57 Furthermore, the presence of 
diabetes increases the probability of a poorer outcome after a cardiovascular event.57 Even pre-
diabetic conditions, such as impaired fasting glucose, impaired glucose tolerance, and insulin 
resistance are associated with increases in cardiovascular risk.57 The continuum – from insulin 
resistance, to impaired glucose tolerance, to impaired fasting glucose, and ultimately to T2DM –
is important to recognize, not only to prevent the ultimate progression to diabetes, but also to 
mitigate the responses that cause increased cardiovascular risks.60 The closer the individuals are 
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to diabetes on this continuum, the greater their cardiovascular risks.60 Metabolic syndrome is a 
good predictor of diabetes, even apart from glucose intolerance.56  
Hyperglycemia results in changes in endothelial, macrophage, and smooth muscle 
function, which ultimately results in atherosclerosis, decreases vascular production of nitric 
oxide necessary for vasodilation and endothelial function, contributes to hypertension, and 
increases plasminogen activator inhibitor-1 to impair thrombolysis.60 Insulin resistance results in 
movement of free fatty acids from adipose tissue to the liver, promoting dyslipidemia of 
hypertriglyceridemia, low HDL, and small, dense LDL.60 HDL levels are lowered in insulin 
resistant states as a hypercatabolic state of HDL is produced.60 Build-up of lipid metabolites in 
liver cells can cause hepatic insulin resistance, as well.60 Insulin resistance is also a 
proinflammatory state, which serves to increase cardiovascular risk.60 Compensatory 
hyperinsulinemia has been linked to insulin resistance, and insulin levels can be a useful 
diagnostic tool.54 Additionally, hyperinsulinemia may play a role in identifying persons with 
metabolic syndrome who may be at increased risk for CVD.59  
 Obesity, body mass index, and waist circumference. 
 Obesity also increases risk for CVD.57, 60 It is associated with other cardiovascular risk 
factors, including the presence of diabetes, dyslipidemia, and hypertension, but research has 
shown that it is also an independent risk factor.57 Research has also focused on weight 
distribution as an important indicator of cardiovascular risk. Upper body obesity, as measured by 
high waist-to-hip ratio and central (abdominal) fat distribution, is associated strongly with insulin 
resistance and metabolic syndrome.54, 57 This may be related to the higher release of fatty acids 
from adipose tissue in upper body obesity, which can result in lipid accumulation in other tissue 
types, and may ultimately contribute to insulin resistance and dyslipidemia.54 Visceral abdominal 
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obesity, in particular, contributes to insulin resistance.60 Waist measurement has been utilized as 
a reliable alternative measure of visceral adipose tissue, which conveys a higher risk of 
metabolic disturbance and cardiovascular events.57 However, Gami et al. performed a systematic 
review of longitudinal studies on metabolic syndrome and cardiovascular risks and determined 
that substituting body mass index (BMI) for waist circumference measurements or waist-to-hip 
ratio did not affect outcomes.58 While waist circumference can be a useful measurement, it must 
be noted that lesser degrees of abdominal width can be associated with other diagnostic criteria, 
and cutoffs can even vary according to ethnicity.54  
 Obesity has also been studied because of its link to breast cancer. Studies have linked 
elevations in BMI to breast cancer, with a relative risk of 1.26 to 2.52.61 This risk appears to be 
present primarily in post-menopausal women; the relationship in premenopausal women is not 
clearly understood, and obesity may actually be protective in this population.61 However, this 
relationship is not clear-cut. BMI is dependent on height, which is also a risk factor for breast 
cancer; weight gain itself has been a much stronger predictor of breast cancer risk, with a 
stronger association seen in weight gained after age 30-40.61 This may be a result of weight gain 
related to increases in peripheral and central adipose tissue, as opposed to the gain of lean body 
weight seen in other age groups.61  
 Dyslipidemia. 
 As previously mentioned, insulin resistant states are associated with a dyslipidemia 
marked by hypertriglyceridemia, low HDL, and small, dense LDL.54, 60 Dyslipidemia can 
exacerbate hepatic insulin resistance, and insulin resistance can also create these lipid 
abnormalities.60 Hypertriglyceridemia results in higher risk of myocardial infarction and stroke 
that is increased in the presence of concurrent hypercholesterolemia.57 Low HDL levels pose an 
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independent risk for cardiovascular events, and are a lipid abnormality frequently found in 
persons with central obesity or T2DM.54, 57 HDL exerts positive effects by drawing cholesterol 
from peripheral tissues to the liver and exerting both anti-inflammatory and anti-oxidant vascular 
effects.57 Because of the high risk conferred by elevated LDL, the primary goal in treatment is 
reduction in LDL cholesterol, even in metabolic syndrome.54 Increasing HDL cholesterol is the 
secondary treatment goal.54 Triglycerides greater than 150mg/dL are cause for concern, with 
lifestyle changes recommended. Levels of 500 or greater place the patient at risk for pancreatitis, 
and therefore should be treated more aggressively with medications.54, 71  
Lipoprotein(a).  
Lipoprotein(a) (Lp(a)) is a lipoprotein consisting of apolipoprotein(a), apolipoprotein 
B100, and LDL bound together.62 Lp(a) levels are largely determined genetically based on 
variations in the apolipoprotein(a) gene, and are fairly resistant to lifestyle and medication 
changes.62 Lp(a) is known to be both thrombogenic and atherogenic; increased blood levels have 
thus been positively associated with cardiovascular risk.62, 63 This relationship exists independent 
of other CVD risk factors, and is now known to be a causal relationship whereby increased Lp(a) 
levels result in premature atherosclerosis and coronary artery disease.62 The mechanisms of this 
effect are incompletely understood. Lp(a) has prothrombotic and anti-fibrinolytic properties, and 
Lp(a) deposits in the vascular intima may increase the rate of atherogenesis.62 Also, Lp(a) levels 
are inversely related to vascular endothelial cell growth factor levels and coronary collateral 
circulation in patients with coronary artery disease.63  
The relationship between Lp(a) and cancer is also incompletely understood. However, it 
is believed that Lp(a) may be involved in tumor angiogenesis. In a prospective study of males 
with lung cancer as compared to controls, Lp(a) levels were correlated with both presence and 
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stage of lung cancer.63 A review of long-term prospective studies performed by The Emerging 
Risk Factors Collaboration, however, found an independent, modest association between Lp(a) 
level and risk of CHD and stroke, but that appeared to be exclusive to vascular outcomes only; 
no association between Lp(a) level and cancer was found, although the population with cancer 
was small and thus unable to be studied based on cancer type.64  
High sensitivity C-reactive protein. 
 With the recent studies revealing the inflammatory nature of atherosclerosis, studies have 
shown that markers, including C-reactive protein (CRP) can be used to predict both 
atherosclerosis and cardiovascular events.54, 57 Metabolic syndrome has also been linked to a 
state of chronic, low-grade inflammation, as manifested by elevated cytokines and acute-phase 
reactants, including CRP.54 Inflammation can exacerbate metabolic syndrome. Inflammatory 
cytokines can induce insulin resistance, and, in obese populations, these cytokines are produced 
in larger amounts.54 CRP levels may also help to identify persons at increased risk for T2DM.59 
Elevated CRP levels are indicative of an elevated risk that requires lifestyle changes.54     
 However, it is important to note that CRP, as a marker of inflammation, can be elevated 
for other reasons, as well. Inflammatory diseases, such as rheumatoid arthritis and lupus, for 
example, and other conditions, such as recent infections or recent surgery, can also result in 
elevated CRP.65 Furthermore, studies have shown that breast cancer itself is associated with an 
elevation in CRP.66 Chronic inflammation may play a role in both the development and 
progression of breast cancer, although no associations have been noted between elevations in 




The emergence of cardiovascular disease risk and breast cancer. 
In their study of five-year breast cancer survivors, Chapman et al. showed that non-breast 
cancer-related deaths were more common than cancer-related deaths, accounting for 60% of 
known deaths (72% in subjects aged 70 years or older and 48% for those younger than 70 
years).3 Patients may be at risk for non-breast cancer-related illnesses before, during, or after 
breast cancer treatment.3 It is important to note again that most women are diagnosed with breast 
cancer after the age of 40,1 which correlates with the increased lifetime risk of developing CVD 
noted in this age group.4 Risks of developing both breast cancer and CVD increase with age. 
Furthermore, increasing age is associated with increased risk of non-breast cancer-related death, 
and, in a study of five-year breast cancer survivors, the presence of CVD at baseline was linked 
to mortality.3 Consequently, not only are these women already faced with a high lifetime risk of 
developing CVD, but they may also be at an increased risk because of their breast cancer 
diagnoses and treatments.  
Treatment-induced cardiotoxicity. 
As the number of breast cancer survivors and the length of survival after therapy 
increase, the long-term side effects of cancer therapy become apparent. Treatment with 
anthracyclines is known to increase risk of cardiac dysfunction manifested by a decrease in left 
ventricular ejection fraction (LVEF).6-78910111213, 17 This cardiotoxicity can be defined as: mild, 
with a decrease in LVEF of 10% from baseline with a final value of at least 50%; moderate, with 
a decrease of at least 10% with a final value below 50% but no signs or symptoms of heart 
failure; or severe, with a decrease of at least 10% with a final value below 50% and signs or 
symptoms of heart failure or any decrease resulting in a value below 40%.68 The risk of a 
cardiotoxic decrease in LVEF with anthracyclines is dose-dependent and irreversible.69 
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Treatment with anthracyclines and trastuzumab has resulted in increased risk individually and in 
combination.8-91011, 13-1415161718 
Furthermore, risk factors including older age, lower baseline LVEF, and use of 
antihypertensive medications are correlated with increased risk of cardiac dysfunction in patients 
receiving both an anthracycline and trastuzumab,13 suggesting that the presence of CVD risk 
factors prior to therapy can be an independent predictor of treatment-related cardiotoxicity.9 In 
addition, a study of women with breast cancer treated with adjuvant chemotherapy containing 
taxanes and anthracyclines revealed more CVD risk factors as a result of their treatment than 
their age-matched healthy controls.8 The “multiple-hit” hypothesis encompasses these findings, 
and describes CVD risk in women diagnosed with breast cancer as additive. Study results 
demonstrated baseline CVD risk factors, combined with therapy-induced risk factors and 
lifestyle changes during treatment, all contributed to the development of clinical or sub-clinical 
CVD.9  
Screening and surveillance for cardiac risk. 
 The American Heart Association recommends that primary care providers begin 
assessing cardiovascular risks when clients reach age 20.70 This risk assessment should include 
family history, smoking, alcohol, diet, physical activity, blood pressure, BMI, waist 
circumference, pulse, fasting serum lipid profile, and fasting blood glucose.70 If risk factors are 
present, a complete assessment should be done every 2 years; if none are present, it is 
recommended every 5 years.70 NCEP-ATP III guidelines concur with these recommendations.71 
Ten-year risk of CHD with a multiple risk score is also recommended.70 This can be calculated 
through the FRACHD,71 or, more broadly, through the FGCVRAS, as described above (see also 
Appendix A).   
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Operational Definitions 
CVD risk was measured by the Framingham General Cardiovascular Risk Assessment 
Score (FGCVRAS) and the heart/vascular age calculation. D’Agostino et al. developed an 
updated 10-year risk assessment for general CVD that includes age, total cholesterol, HDL, 
systolic blood pressure, use of antihypertensive medications, smoking, and diabetes, calculating 
both a risk score and an estimated vascular age, as previously described.52 The tool was reviewed 
by Marma and Lloyd-Jones (2009), who determined that the inclusion of noncoronary endpoints 
expanded predicted risk, but younger individuals with high risk burdens could have a low 10-
year risk, thus accentuating the importance of including the vascular age component in 
communicating risk.72 The heart/vascular age calculation begins with measured CVD risk in an 
individual, and, given the population characteristics, translates this risk into the age at which 






 This study is part of a larger, prospective longitudinal study describing cardiovascular 
risk factors of women newly diagnosed with breast cancer before and after adjuvant treatments 
with therapies known to result in cardiac toxicity (anthracyclines and/or trastuzumab). This 
portion is a descriptive correlational study that describes the cardiovascular health of women 
newly diagnosed with breast cancer prior to beginning adjuvant chemotherapy with 
anthracyclines and/or trastuzumab as measured by the FGCVRAS and heart/vascular age 
calculation. In this section, the setting, sample, instruments, procedure for data collection, and 
data analysis will be discussed.  
Setting 
 Subjects were from the Yale Cancer Center Breast Service, an outpatient healthcare 
setting in New Haven, CT.  
Sample 
Medical oncologists, nurses, and nurse practitioners working in the Breast Service 
identified potential subjects; a research assistant contacted those subjects who expressed interest. 
The principal investigator or research assistant explained the study and obtained informed 
consent. A convenience sample of 30 women receiving evaluation and treatment at the Yale 
Cancer Center Breast Service was studied. Inclusion criteria included a diagnosis of invasive 
breast cancer, scheduled adjuvant treatment with anthracyclines and/or trastuzumab, and ability 
to communicate in English. Exclusion criteria included serious cognitive impairment.  
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Data Collection Instruments 
The FGCVRAS was conducted at baseline. This score, recently updated by D’Agostino 
et al., now encompasses risk for CVD as a whole; this multivariate, gender-specific assessment is 
interpreted based on the Cox Hazard Mathematical Model, and assigns point values to the 
aforementioned risk factors to obtain an absolute 10-year risk.53 This instrument has been 
documented as effective in measuring CVD risk in both men and women.53, 72  
The heart/vascular age calculation was also conducted at baseline (please see Appendix 
B). The heart/vascular age calculation begins with measured CVD risk in an individual, and 
given population characteristics, translates this risk into the age at which another person would 
experience this risk, level given no other risk factors.53, 73  
Data Collection Procedures 
 Approval for the parent study was obtained from the Yale University Institutional Review 
Board. Data collection for the parent study began in October 2010, with baseline data collection 
completed in February 2012. Medical oncologists and nurse practitioners working with the 
Breast Service approached eligible subjects. The principal investigator or research assistant 
contacted those interested in participating, described the study, answered any questions, and 
obtained informed consent. Prior to the first chemotherapy, fasting blood samples were obtained, 
including glucose and lipid panel (total cholesterol, LDL, HDL, triglycerides). High-sensitivity 
C-reactive protein (hs-CRP), lipoprotein (a), and insulin levels were also obtained as fasting 
blood samples. Other baseline data included weight, height, calculated BMI, waist 
circumference, and mean systolic and diastolic blood pressure. These values were utilized to 





Using the Statistical Package for the Social Sciences (SPSS for Windows, version 19) 
computer program, measures of central tendency and descriptive statistics were used to interpret 
the data obtained from the FGCVRAS and heart/vascular age calculation.  
Sample Characteristics 
 Demographic characteristics are presented in Table 1. In summary, the sample included 
30 women of mean age 49.97 years (range 33 to 72 years, SD 9.926), with 93.3% self-reporting 
white ethnicity, 66.7% married, and 80% with children. All participants completed a minimum 
of four years of high school education, with 30% completing four years of college, and 33% 
completing graduate school. 63.3% worked full-time and 6.7% worked part time. 90% earned an 
income of >60,000 USD/year. Four women had a history of diabetes, 10 had a history of 







Baseline data is presented in Table 2. Data was available for 29 subjects; laboratory 
information was not obtained for one subject.   
 
Analysis 
Average CVD risk was calculated according to the FGCVRAS, with an average risk of 
5.58% (SD 5.68). Average heart/vascular age was 49.62 years (SD 18.33). Nine women had 
calculated heart/vascular ages that exceeded their physical ages (Table 3). At a cardiovascular 
risk of approximately 5.3%, vascular age began to exceed actual age. Using the NCEP 
definition,56 six women met the criteria for metabolic syndrome; using the IDF definition,56 five 
women met these criteria (Table 4). Fourteen women had at least two cardiovascular risk factors 
(increased waist circumference, increased fasting blood glucose, increased triglycerides, 
decreased HDL, or elevated systolic/diastolic blood pressure) (Table 4). A breakdown of 







Dr. Anthony J. Guarino of the Massachusetts General Hospital Institute of Health 
Professions (MGH IHP) was consulted for additional data analysis. A simultaneous multiple 
regression analysis was performed to evaluate how the 11 predictor variables measured 
(cholesterol, LDL, triglycerides, HDL, glucose, insulin, waist circumference, CRP, BMI, mean 
BPS, and mean BPD) could account for and predict cardiovascular risk. The linear combination 
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of these 11 predictors was found to be statistically significantly related to cardiovascular risks 
(F(11, 13) = 10.01, p < .001). The sample multiple correlation coefficient was 0.95, 
demonstrating that the regression accounted for approximately 89% of the variance of 
cardiovascular risks. Only 4 of the 11 predictors (HDL, glucose, waist circumference, and mean 
BPS) were statistically significant. A multiple regression performed with only these predictors 
resulted in similar results, including a multiple correlation coefficient of 0.91.  
The regression equation developed to predict cardiovascular risk is: 
Y = -29 -.02X1 - .02x2 + .005x3 + .002x4 
Where X1 = HDL,   X2 = glucose, X3 = waist circumference, and X4 = mean BPS.  







 This study reveals that, at breast cancer diagnosis, women have significant CVD risk. 
However, the overwhelming majority of women in this study did not have cardiovascular risk 
assessments done by their primary care providers as is recommended by the American Heart 
Association and NCEP-ATP III guidelines;70, 71 although all women report routine care by a 
primary care provider and insurance coverage, only 3 out of 30 women recalled ever having a 
cardiovascular risk assessment. Unfortunately, as described above, studies have demonstrated 
that cardiovascular assessments are not always done as recommended.49, 50  
In this sample, the known CVD risk factors that most contributed to CVD risk as 
calculated by the FGCVRAS were HDL, glucose, waist circumference, and systolic blood 
pressure. While these variables, in addition to others, are all utilized in calculating the 
FGCVRAS, it is notable that these variables predicted the overwhelming majority of the CVD 
risk in this population of women newly diagnosed with breast cancer. This should be followed as 
the study sample grows – and throughout treatment with adjuvant chemotherapy – to determine 
if these variables continue to be the most important predictors of CVD risk for this population.  
At baseline, women in this population also had a significant amount of CVD risk. Six out 
of 29 women met criteria for diagnosis of metabolic syndrome at baseline. As previously 
described, research indicates that breast cancer treatment with chemotherapy results in weight 
gain and increased waist circumference.25 Consequently, over the next six months to one year, 
we can anticipate an emergence of increased CVD risk with a concurrent increase in the number 
of women meeting the criteria for metabolic syndrome diagnoses.  
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  A striking correlation between elevated Lp(a) with triple-negative breast cancer, although 
anecdotal, was noted. In a sample of 29 women, 5 had elevated Lp(a). Research has shown that 
roughly 20% of Caucasians have Lp(a) of greater than 50mg/dL.62 However, all of the elevated 
Lp(a) levels in this study were seen in women with triple-negative breast cancer.  This 
phenomenon warrants further exploration and research.  
Conclusion 
Women diagnosed with breast cancer have baseline risk factors for CVD that need to be 
assessed and addressed prior to beginning potentially cardiotoxic treatments. At baseline, women 
diagnosed with breast cancer demonstrate a significant risk burden for CVD, and, at the same 
time, are not receiving the preventative care recommended by national guidelines. This risk 
requires further research, especially as it pertains to describing how the risk is altered by 
cardiotoxic cancer therapies.  
Limitations 
 This study has several limitations. First, the sample size is small at 30 subjects. Data 
collection is ongoing as part of a larger parent study. This study describes only baseline 
characteristics of a population, and consequently cannot comment on interventions or causative 
factors directly. The baseline study characteristics included primarily well-educated Caucasian 
women with significant income. Data was collected after women were formally diagnosed with 
breast cancer; consequently, while this study can describe women with breast cancer at baseline, 
it cannot speak to the causative effects of breast cancer on CVD, or vice versa.  
Summary of Research and Future Directions 
 Research has focused on identifying risk factors associated with CVD and subsequent 
predictive analyses, with a focus on prevention and early detection; while this research has 
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expanded to include information specific to CVD in women, there is no data specific to CVD in 
women with breast cancer. The same can be said of breast cancer research. There is significant 
research describing women’s risks for developing breast cancer, with a focus on prevention and 
early detection. With the introduction of anthracyclines and trastuzumab as staples in breast 
cancer treatment, research has thus far focused on the relationships between these therapies and 
primarily left ventricular dysfunction.  
Little research exists to describe the cardiovascular risk factors of women newly 
diagnosed with breast cancer. Research in this area would allow early detection of risk and, 
consequently, prevention of CVD in women with breast cancer. This research would also 
potentially lay the groundwork for future research focusing on predicting treatment-related 
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Appendix A: FGCVRAS 53 
CVD Points 








<-3    <120    
-2  60+      
-1  50-59   <120   
0 30-34 45-49 <160 120-129  No No 
1  35-44 160-199 130-139    
2 35-39 <35  140-149 120-129   
3   200-239  130-139 Yes  
4 40-44  240-279 150-159   Yes 
5 45-49  280+ 160+ 140-149   
6     150-159   
7 50-54    160+   
8 55-59       
9 60-64       
10 65-69       
11 70-74       
12 75+       
 
CVD Risk 
Points Risk Points Risk Points Risk 
-2 or less Below 1% 6 3.3% 14 11.7% 
-1 1.0% 7 3.9% 15 13.7% 
0 1.2% 8 4.5% 16 15.9% 
1 1.5% 9 5.3% 17 18.5% 
2 1.7% 10 6.3% 18 21.5% 
3 2.0% 11 7.3% 19 24.8% 
4 2.4% 12 8.6% 20 28.5% 




Appendix B: Heart/Vascular Age Score 53 
 
Heart Age Points Heart Age 
Younger than 30 8 51 
31 9 55 
34 10 59 
36 11 64 
39 12 68 
45 13 73 
45 14 79 
48 15+ Older than 80 
   
 
